A regional analysis of epidermal growth factor receptor (EGFR) mutated lung cancer for HSE South

Abstract

The incidence of EGFR mutation in our cohort of NSCLC is 9% which is consistent with mutation incidence reported in other countries. The rate of EGFR mutation in our population is slightly below that reported internationally, but treatment outcomes are consistent with published data. Real-world patient data have important contributions to make with regard to quality measurement, incorporating patient experience into guidelines and identifying safety signals.

Genomic Landscape of NSCLC in the Republic of Ireland

“…A previous study by Kelly et al. 27 also reported a prevalence of 9% for EGFR mutations in the South of Ireland. Broader molecular testing such as whole exome, genome, or transcriptome sequencing may identify other alterations that contribute to lung cancer pathogenesis that are missed using targeted NGS, such as alterations in tumor suppressor genes STK11 and TP53 .…”

“… 20 , 26 We report an overall prevalence of 9% in our cohort; however, this is largely consistent with a previous study which detected an EGFR prevalence of 9% in the South of Ireland. 27 In contrast to this, Shikhrakab et al. 28 revealed an EGFR prevalence of 13.8% among 209 Irish patients tested for the mutation.…”